Beacon Pointe Advisors’s Viking Therapeutics VKTX Stock Holding History

Beacon Pointe Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$381K	Sell	9,756 -11	-0.1%	-$355	﹤0.01%	1472
2026 Q1	$318K	Buy	9,767 +1,254	+15%	+$40.3K	﹤0.01%	1505
2025 Q4	$299K	Sell	8,513 -3,562	-29%	-$126K	﹤0.01%	1262
2025 Q3	$317K	Sell	12,075 -7,724	-39%	-$230K	﹤0.01%	1162
2025 Q2	$525K	Sell	19,799 -13,280	-40%	-$350K	0.01%	869
2025 Q1	$799K	Sell	33,079 -1,400	-4%	-$44.2K	0.01%	698
2024 Q4	$1.39M	Buy	34,479 +1,615	+5%	+$92.1K	0.02%	554
2024 Q3	$2.08M	Buy	+32,864	New	+$1.93M	0.02%	465

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Beacon Pointe Advisors's VKTX Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its Viking Therapeutics (VKTX) stake by 0.11% in Q2 2026, selling an estimated $355 and leaving 9,756 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #1472.

Beacon Pointe Advisors first reported a position in VKTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.08M in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Beacon Pointe Advisors held 9,756 shares of Viking Therapeutics worth $381K as of Q2 2026.
Beacon Pointe Advisors sold 11 Viking Therapeutics shares in Q2 2026, an estimated $355.
Viking Therapeutics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1472 holding.
Beacon Pointe Advisors first reported a position in Viking Therapeutics in Q3 2024 and has held it in 8 quarters since.
Beacon Pointe Advisors's Viking Therapeutics position peaked at $2.08M in Q3 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.